Table 1. Demographic and Clinical Characteristics of Patients Who Underwent Whole-Exome Sequencing .
| Variable | Best Responder Group | Nonresponder Group |
|---|---|---|
| No. | 156 | 160 |
| Male, No. (%) | 68 (43.6) | 82 (51.2) |
| Female, No. (%) | 88 (56.4) | 78 (48.8) |
| Age, mean (SD), y | 25.7 (7.7) | 25.9 (7.3) |
| Antipsychotic drugs | ||
| Olanzapine, 5-20 mg | 24 (15.4) | 33 (20.6) |
| Quetiapine fumarate, 400-750 mg | 25 (16.0) | 31 (19.4) |
| Ziprasidone hydrochloride, 80-160 mg | 29 (18.6) | 21 (13.1) |
| Aripiprazole, 10-30 mg | 20 (12.8) | 26 (16.3) |
| Risperidone, 2-6 mg | 25 (16.0) | 21 (13.1) |
| Perphenazine, 20-60 mg | 19 (12.2) | 19 (11.9) |
| Haloperidol lactate, 6-20 mg | 14 (8.9) | 9 (5.6) |
| PANSS total score, mean (SD), % | ||
| Baseline | 87.4 (6.8) | 86.0 (6.9) |
| 6 wk | 35.8 (3.0) | 87.8 (12.1) |
| PANSS positive symptom score, mean (SD), % | ||
| Baseline | 24.9 (3.6) | 25.5 (3.5) |
| 6 wk | 8.1 (1.3) | 22.0 (5.3) |
| PANSS negative symptom score, mean (SD), % | ||
| Baseline | 21.4 (5.1) | 21.1 (4.8) |
| 6 wk | 8.7 (1.3) | 23.8 (5.2) |
| PANSS general psychopathologic score, mean (SD), % | ||
| Baseline | 41.1 (5.0) | 40.4 (4.8) |
| 6 wk | 19.1 (2.0) | 42.0 (7.1) |
| Percentage reduction in PANSS total scorea | 90 (5) | −4 (20) |
Abbreviation: PANSS, Positive and Negative Syndrome Scale (score range: 60-90, with the highest score indicating the most severe symptoms).
a
Calculated as 100 × (baseline – 6 weeks) / (baseline – 30).